← Back to Search

NMDA Receptor Antagonist

Ketamine for Suicidal Thoughts

Phase 1
Recruiting
Research Sponsored by Lindsay Maguire, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Hypertension (SBP > 180 or DBP > 100)
Imprisonment or inability to consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if ketamine can be used to reduce suicidal thoughts in those who present to an Emergency Dept.

Who is the study for?
This trial is for individuals in the emergency department with suicidal thoughts or behaviors, who are fully conscious (GCS 15). It's not suitable for those with a history of psychosis, clinical intoxication, extreme blood pressure issues, pregnancy, inability to consent, known adverse reactions to ketamine, involuntary psychiatric hold or those needing medical admission.
What is being tested?
The study tests low-dose intravenous ketamine as an immediate treatment for patients presenting with suicidal ideation in the emergency department. The goal is to see if it's feasible and safe to use this drug that has shown promise in treating resistant depression.
What are the potential side effects?
Ketamine can cause side effects such as disorientation, changes in blood pressure and heart rate, dizziness, nausea or vomiting. Some people might experience mood swings or feel detached from reality temporarily.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My blood pressure is not higher than 180/100.
Select...
I am not imprisoned and can make my own medical decisions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Provider and Nursing Attitudes toward use of Ketamine for Suicidal Patients in the ED [Feasibility]
Secondary study objectives
Change in Suicidal Ideation
Hospital Length of Stay

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: KetamineExperimental Treatment1 Intervention
All patients will receive the experimental drug.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
2011
Completed Phase 4
~1120

Find a Location

Who is running the clinical trial?

Lindsay Maguire, MDLead Sponsor
University of Kansas Medical CenterLead Sponsor
517 Previous Clinical Trials
177,248 Total Patients Enrolled
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top